132015-95-3 Usage
Uses
Used in Pharmaceutical Industry:
(1R,3R,7E,22E,24R)-24-methyl-19-nor-9,10-secocholesta-5,7,22-triene-1,3,25-triol is used as a pharmaceutical compound for its potential biological activity. Its unique molecular structure and the presence of hydroxyl groups may contribute to its interaction with biological targets, making it a candidate for the development of new drugs or therapies.
Used in Research and Development:
(1R,3R,7E,22E,24R)-24-methyl-19-nor-9,10-secocholesta-5,7,22-triene-1,3,25-triol is used in research and development to study its properties and functions. Understanding its role in physiological processes can provide insights into its potential applications in medicine and other fields, as well as contribute to the advancement of scientific knowledge.
Used in Drug Delivery Systems:
(1R,3R,7E,22E,24R)-24-methyl-19-nor-9,10-secocholesta-5,7,22-triene-1,3,25-triol can be used in drug delivery systems to improve the efficacy and bioavailability of other pharmaceutical compounds. Its unique structure and functional groups may allow for the development of novel drug delivery platforms, enhancing the therapeutic outcomes of various treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 132015-95-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,2,0,1 and 5 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 132015-95:
(8*1)+(7*3)+(6*2)+(5*0)+(4*1)+(3*5)+(2*9)+(1*5)=83
83 % 10 = 3
So 132015-95-3 is a valid CAS Registry Number.
132015-95-3Relevant academic research and scientific papers
Synthesis and crystallographic study of 1,25-dihydroxyergocalciferol analogs
Pietraszek, Anita,Malińska, Maura,Chodyński, Michal,Krupa, Malgorzata,Krajewski, Krzysztof,Cmoch, Piotr,Wo?niak, Krzysztof,Kutner, Andrzej
, p. 1003 - 1014 (2013/10/21)
The hybrid analogs of 1,25-dihydroxyergocalciferol (PRI-5201 and PRI-5202) were synthesized as potential anticancer agents using a convergent strategy. The analogs were designed by combining a 19-nor modification of the A-ring with the homologated and rig
NEW SYNTHONES FOR PREPARATION OF 19-NOR VITAMIN D DERIVATIVES
-
, (2013/02/28)
The present invention discloses the synthone of Formula (I), wherein R1 and R2 are the same or different and represent independently hydrogen atom or hydroxyl protecting group, and its use for preparation of 19-nor vitamin D derivatives of general Formula (IV), wherein represents single or double bond, p represents an integer 0 to 3, R1 and R2 represent independently hydrogen atom or hydroxyl protecting group, R3 represents hydrogen atom, CH3 or hydroxyl group, R4, R5 and R6 represent independently hydrogen atom, C1-C3-alkyl or hydroxyl group or two of R4, R5 and R6 substituents altogether form cyclopropyl group, in particular for preparation of paricalcitol.
